Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

PDF files are a mainstay in our multi-platform world. This convenient file format makes viewing and sharing documents across various devices using various operating systems and software programs ...

Overview: The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the ...

After 31 days with Molty, our persistent AI agent, the real question isn't whether memory makes AI more capable. It's what ...

Educational achievement gaps persist globally, with some ethnic minority and socioeconomically disadvantaged students consistently underperforming. Self-affirmation interventions, brief ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...